3 results ยท Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing TreatmentDigestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bile duct disorder, biliary tract disorder, cholestasis, cirrhosis of liver, intrahepatic cholestasis, liver disorder, primary biliary cholangitisActive, not recruitingNot stated2026-10-01NCT06447168
A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary CholangitisDigestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bile duct disorder, biliary tract disorder, cholestasis, cirrhosis of liver, intrahepatic cholestasis, liver disorder, primary biliary cholangitisRecruitingPhase 32026-10-01NCT06016842
The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, cutaneous lupus erythematosus, discoid lupus erythematosus, immune system disorder, skin disorder, systemic lupus erythematosusActive, not recruitingPhase 22026-07-20NCT05540327